Sarcopenia Treatment Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2017 to 2021 and Forecast 2022 to 2028

$ PRICE - $ 3,000.00$ 8,900.00

Sarcopenia Treatment  Market By Treatment Type (Protein Supplement, Vitamin B12 Supplement, Vitamin D & Calcium Supplement, and Others), Route Of Administration (Oral, Parenteral, and Enteral), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others), and Geography

 

$ PRICE - $ 3,000.00$ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00$ 8,900.00
FacebookTwitterLinkedinEmail
SKU: N/A Category:

Report

Description

Sarcopenia Treatment Market size is expected to be valued at USD 2775.2 million in 2022 and is poised to grow at a significant CAGR of 6.4% over 2022–2028. Sarcopenia refers to the loss of skeletal muscle mass or flesh as a result of an aging population. Sarcopenia is considered by a reduction in muscular size, relative weakness, lack of stamina, difficulties to mounting stairs, and poor balance. Sarcopenia can consequence in a worse quality of life as well as disability. Sarcopenia is caused primarily by malnutrition. In developing and poor countries, micronutrient-rich foods are consumed in low amounts, resulting in malnutrition. As a result, there is no recognized treatment for sarcopenia; nevertheless, proper nutrition and dietary supplements can help with the condition.  A rising aging population, and deficiencies of vitamin D and vitamin B12 among a large section of people are primary factors driving the market growth of the sarcopenia treatment Market. Additionally, the increasing demand for protein and vitamin supplements also support to enhances the market demand. On the other hand, Sarcopenia Treatment Market is constrained by a lack of public knowledge of muscle loss, the high cost of protein supplements, and the lack of sarcopenia treatment medications. Nevertheless, numerous industries are focused on research and development efforts as well as clinical trials for age-related muscle mass loss, which is expected to growth of the Global sarcopenia treatment market with enormous potential prospects. Moreover, several pharmaceutical and food-processing businesses are making investments in the production of novel infant nutrition supplements to focus on the treatment of sarcopenia is further expected to boost the market growth.

Recent Market Developments:

In February 2022, MyMD Pharmaceuticals announced positive clinical data before the upcoming Phase II Trial of MYMD-1 drug candidates. MYMD-1 is a novel immunotherapy drug developed with the primary purpose of slowing the aging process, preventing sarcopenia and frailty, and extending a healthy lifespan.

Sarcopenia Treatment Market

MARKET SUMMARY
-
6.4%
  • Study Period– 2022 – 2028
  • Base Year– 2021
  • CAGR– 6.4%
  • Largest Market– Asia Pacific
  • Fastest Growing Market– North America

Sarcopenia Treatment Market

  • The report on global sarcopenia treatment market gives historical, current and future market sizes (US$ Mn) on the basis of treatment type, route of administration, distribution channel, and geography.
  • The sarcopenia treatment market report gives comprehensive outlook across the region with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
Key Players
  • Sanofi
  • Novartis AG
  • Pfizer Inc.
  • AstaReal AB
  • Dohme Corp.
Sarcopenia Treatment Market Dynamics

The global market for Sarcopenia Treatment is growing due to the increasing aging population. For instance, As per the study published in Intech Open Journal, 2017, people aged 60 or over are projected to increase from 841 million to above 2 billion between 2013 and 2050. Thus, equating the geriatric population to 21.1% of the worldwide population. Furthermore, sarcopenia increases the risk of falls and fractures, as aging patients with sarcopenia have muscle loss, reducing strength and function. Thus, the Sarcopenia Treatment market is expanding by the rise in the geriatric population worldwide over the forecasted period.


North-America Got Significant Share

Sarcopenia Treatment Market

North America is expected to dominate the global market of sarcopenia treatment owing to the existence of well-developed healthcare facilities and continuous technological advancements. Furthermore, sarcopenia affected people increasing day by day, owing to the increased prevalence of the geriatric population, and the presence of prominent players in the market. These factors surely increase the demand for sarcopenia treatment, and support to expands the market in this region.

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East

Key

Features of the Report

  • The sarcopenia treatment market report provides granular level information about the market size, regional market share, historic market (2017-2021), and forecast (2022-2028)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
Sarcopenia Treatment Market Segmentation


Location

GEOGRAPHY

Frequently Asked Questions

Sarcopenia refers to the loss of skeletal muscle mass or flesh as a result of an aging population. Sarcopenia is considered by a reduction in muscular size, relative weakness, lack of stamina, difficulties to mounting stairs, and poor balance.

Key players’ profiles in the sarcopenia treatment market report are are GlaxoSmithKline plc, Nestle Health Science, Sanofi S.A., Bayer AG, Cadila Healthcare Ltd, Eli Lilly and Company, GlaxoSmithKline plc., Sanofi, Novartis AG, Pfizer Inc.

A rise in the geriatric population, an increase in malnutrition and vitamin deficiency in developing countries, and growing per capita healthcare expenditure.


Report

Table Of Content

1. Executive Summary
2. Global Sarcopenia Treatment Market Introduction
2.1. Global Sarcopenia Treatment Market – Taxonomy
2.2. Global Sarcopenia Treatment Market –Definitions
2.2.1. Treatment Type
2.2.2. Route Of Administration
2.2.3. Distribution Channel
2.2.4. Region
3. Global Sarcopenia Treatment Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Sarcopenia Treatment Market Dynamic Factors – Impact Analysis
3.6. Global Sarcopenia Treatment Market – Competition Landscape
4. Global Sarcopenia Treatment Market Analysis,2017 – 2021 and Forecast, 2022 – 2028
4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis
5. Global Sarcopenia Treatment Market, By Treatment Type, 2017–2021 and Forecast, 2022–2028 (Revenue, USD Mn)
5.1. Protein Supplement
5.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Vitamin B12 Supplement
5.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. Vitamin D & Calcium Supplement
5.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
5.4. Others
5.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.4.3. Market Opportunity Analysis
6. Global Sarcopenia Treatment Market, By Route Of Administration, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.1. Oral
6.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Parenteral
6.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Enteral
6.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
7. Global Sarcopenia Treatment Market Forecast, By Distribution Channel,2017–2021 and Forecast, 2022–2028 (Revenue, USD Mn)
7.1. Hospital Pharmacies
7.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Retail Pharmacies
7.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Online Pharmacies
7.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
7.4. Others
7.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.4.3. Market Opportunity Analysis
8. Global Sarcopenia Treatment Market Forecast, By Region, 2017–2021 and Forecast, 2022–2028(Revenue, USD Mn)
8.1. North America
8.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.1.3. Market Opportunity Analysis
8.2. Europe
8.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.2.3. Market Opportunity Analysis
8.3. Asia-Pacific
8.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.3.3. Market Opportunity Analysis
8.4. Latin America
8.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.4.3. Market Opportunity Analysis
8.5. Middle East and Africa
8.5.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.5.3. Market Opportunity Analysis
8.6. Global Sarcopenia Treatment Market – Opportunity Analysis Index, By Treatment type, Route of Administration, Distribution Channel, and Region, 2022 – 2028
9. North America Sarcopenia Treatment market analysis,2017–2021 and Forecast, 2022–2028(Revenue, USD Mn)
9.1. Treatment Type Analysis 2017–2021and Forecast 2022 – 2028by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.1.1. Protein Supplement
9.1.2. Vitamin B12 Supplement
9.1.3. Vitamin D & Calcium Supplement
9.1.4. Others
9.2. Route Of Administration Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.2.1. Oral
9.2.2. Parenteral
9.2.3. Enteral
9.3. Distribution Channel Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.3.1. Hospital Pharmacies
9.3.2. Retail Pharmacies
9.3.3. Online Pharmacies
9.3.4. Others
9.4. Country Analysis 2017 – 2021 and Forecast 2022 – 2028by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
9.4.1. USA
9.4.2. Canada
9.5. North America Sarcopenia Treatment Market – Opportunity Analysis Index, By Treatment type, Route of Administration, Distribution Channel, and Country, 2022 – 2028
9.6. North America Sarcopenia Treatment Market Dynamics – Trends
10. Europe Sarcopenia Treatment Market Analysis, 2017–2021 and Forecast, 2022–2028(Revenue, USD Mn)
10.1. Treatment Type Analysis 2017–2021and Forecast 2022 – 2028by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.1. Protein Supplement
10.1.2. Vitamin B12 Supplement
10.1.3. Vitamin D & Calcium Supplement
10.1.4. Others
10.2. Route Of Administration Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.2.1. Oral
10.2.2. Parenteral
10.2.3. Enteral
10.3. Distribution Channel Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.3.1. Hospital Pharmacies
10.3.2. Retail Pharmacies
10.3.3. Online Pharmacies
10.3.4. Others
10.4. Country Analysis 2017–2021and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
10.4.1. Germany
10.4.2. UK
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Russia
10.4.7. Poland
10.4.8. Rest of Europe
10.5. Europe Sarcopenia Treatment Market – Opportunity Analysis Index, By Treatment Type, Route Of Administration, Distribution Channel, and Country, 2022 – 2028
10.6. Europe Sarcopenia Treatment Market Dynamics – Trends
11. Asia-Pacific Sarcopenia Treatment Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
11.1. Treatment Type Analysis 2017–2021and Forecast 2022 – 2028by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.1. Protein Supplement
11.1.2. Vitamin B12 Supplement
11.1.3. Vitamin D & Calcium Supplement
11.1.4. Others
11.2. Route Of Administration Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.2.1. Oral
11.2.2. Parenteral
11.2.3. Enteral
11.3. Distribution Channel Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.3.1. Hospital Pharmacies
11.3.2. Retail Pharmacies
11.3.3. Online Pharmacies
11.3.4. Others
11.4. Country Analysis2017–2021and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
11.4.1. Japan
11.4.2. China
11.4.3. India
11.4.4. ASEAN
11.4.5. Australia & New Zealand
11.4.6. Rest of Asia-Pacific
11.5. Asia-Pacific Sarcopenia Treatment Market – Opportunity Analysis Index, By Treatment type, Route of Administration, Distribution Channel, and Country,2022 – 2028
11.6. Asia-Pacific Sarcopenia Treatment Market Dynamics – Trends
12. Latin America Sarcopenia Treatment Market Analysis,2017 – 2021 and Forecast, 2022–2028(Revenue, USD Mn)
12.1. Treatment Type Analysis 2017–2021and Forecast 2022 – 2028by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.1. Protein Supplement
12.1.2. Vitamin B12 Supplement
12.1.3. Vitamin D & Calcium Supplement
12.1.4. Others
12.2. Route Of Administration Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.2.1. Oral
12.2.2. Parenteral
12.2.3. Enteral
12.3. Distribution Channel Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.3.1. Hospital Pharmacies
12.3.2. Retail Pharmacies
12.3.3. Online Pharmacies
12.3.4. Others
12.4. Country Analysis 2017–2021and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Argentina
12.4.4. Rest of Latin America
12.5. Latin America Sarcopenia Treatment Market – Opportunity Analysis Index, By Treatment type, Route of Administration, Distribution Channel, and Country, 2022 – 2028
12.6. Latin America Sarcopenia Treatment Market Dynamics – Trends
13. Middle East and Africa Sarcopenia Treatment Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
13.1. Treatment Type Analysis 2017–2021and Forecast 2022 – 2028by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.1. Protein Supplement
13.1.2. Vitamin B12 Supplement
13.1.3. Vitamin D & Calcium Supplement
13.1.4. Others
13.2. Route Of Administration Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.2.1. Oral
13.2.2. Parenteral
13.2.3. Enteral
13.3. Distribution Channel Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.3.1. Hospital Pharmacies
13.3.2. Retail Pharmacies
13.3.3. Online Pharmacies
13.3.4. Others
13.4. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
13.4.1. Gulf Cooperation Council (GCC) Countries
13.4.2. Israel
13.4.3. South Africa
13.4.4. Rest of MEA
13.5. MEA Sarcopenia Treatment Market – Opportunity Analysis Index, By Treatment type, Route of Administration, Distribution Channel, and Country, 2022 – 2028
13.6. MEA Sarcopenia Treatment Market Dynamics – Trends
14. Competition Landscape
14.1. Strategic Dashboard of Top Market Players
14.2. Company Profiles (Introduction, Financial Analysis, Product Type& Service Testing Types, Key Developments, Strategies, and SWOT Analysis)
14.2.1. GlaxoSmithKline plc
14.2.2. Nestle Health Science
14.2.3.  Sanofi S.A.
14.2.4. Bayer AG
14.2.5. Novartis AG
14.2.6. Cadila Healthcare Ltd
14.2.7. Eli Lilly and Company
14.2.8. GlaxoSmithKline plc.
14.2.9.  Sanofi
14.2.10.  Pfizer Inc.
14.2.11.  AstaReal AB
14.2.12.  Merck Sharp & Dohme Corp.
14.2.13.  AbbVie Inc.
15. Research Methodology
16. Key Assumptions and Acronyms

Report

Company Profile

  • GlaxoSmithKline plc
  • Nestle Health Science
  • Sanofi S.A.
  • Bayer AG
  • Cadila Healthcare Ltd
  • Eli Lilly and Company
  • GlaxoSmithKline plc.
  • Sanofi
  • Novartis AG
  • Pfizer Inc.
  • AstaReal AB
  • Merck Sharp & Dohme Corp.
  • AbbVie Inc.

Description

Sarcopenia Treatment Market size is expected to be valued at USD 2775.2 million in 2022 and is poised to grow at a significant CAGR of 6.4% over 2022–2028. Sarcopenia refers to the loss of skeletal muscle mass or flesh as a result of an aging population. Sarcopenia is considered by a reduction in muscular size, relative weakness, lack of stamina, difficulties to mounting stairs, and poor balance. Sarcopenia can consequence in a worse quality of life as well as disability. Sarcopenia is caused primarily by malnutrition. In developing and poor countries, micronutrient-rich foods are consumed in low amounts, resulting in malnutrition. As a result, there is no recognized treatment for sarcopenia; nevertheless, proper nutrition and dietary supplements can help with the condition.  A rising aging population, and deficiencies of vitamin D and vitamin B12 among a large section of people are primary factors driving the market growth of the sarcopenia treatment Market. Additionally, the increasing demand for protein and vitamin supplements also support to enhances the market demand. On the other hand, Sarcopenia Treatment Market is constrained by a lack of public knowledge of muscle loss, the high cost of protein supplements, and the lack of sarcopenia treatment medications. Nevertheless, numerous industries are focused on research and development efforts as well as clinical trials for age-related muscle mass loss, which is expected to growth of the Global sarcopenia treatment market with enormous potential prospects. Moreover, several pharmaceutical and food-processing businesses are making investments in the production of novel infant nutrition supplements to focus on the treatment of sarcopenia is further expected to boost the market growth.

Recent Market Developments:

In February 2022, MyMD Pharmaceuticals announced positive clinical data before the upcoming Phase II Trial of MYMD-1 drug candidates. MYMD-1 is a novel immunotherapy drug developed with the primary purpose of slowing the aging process, preventing sarcopenia and frailty, and extending a healthy lifespan.

ASIA PACIFIC OFFICE

Precision Business Insights, MIG 366, SAI PLAZA, 1st Floor, KPHB Colony, Hyderabad - 500072

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX